<DOC>
	<DOCNO>NCT01472757</DOCNO>
	<brief_summary>The purpose study evaluate clinical efficacy three dos VR506 deliver via new dry powder inhaler treatment asthma .</brief_summary>
	<brief_title>Clinical Study Evaluate Efficacy VR506 Using New Inhaler Treatment Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Written inform consent Adolescents age 12 17 year ( inclusive ) adult age 18 65 year ( inclusive ) Documented clinical history asthma ( i.e . make physician ) least 6 month Screening Visit Documented asthma reversibility 5 year prior Screening , asthma reversibility criterion meet Screening , repeat test may carry end RunIn Period Subjects asthma , opinion investigator , require maintenance therapy ICS , believe regularly compliant therapy , therefore likely deteriorate within 6 week follow withdrawal usual ICS treatment Mild moderate asthma , define : Mild good asthma control achieve lowdose inhale corticosteroid ( daily dose 200500 μg beclomethasone dipropionate equivalent ) without lowintensity treatment ( e.g . leukotriene modifier cromones ) least 28 day Screening Visit Moderate good asthma control achieve low moderatedose ICS ( daily dose 2001000 μg beclomethasone dipropionate equivalent ) , long act β2agonist ( LABA ) extra treatment , least 28 day Screening Visit Ability use new inhaler correctly , base investigator 's review complete inhaler operation checklist Ability use eDiary correctly , assess investigator Screening Period Ability perform technically satisfactory pulmonary function test Ability comply study procedure , include blood sample Body mass index ( BMI ) 16.0 26.0 kg/m2 adolescent , adult subject recruit Philippines , 18.0 32.0 kg/m2 adult recruit country Available complete study visit Oral peak inspiratory flow ( PIF ) least 60 L/min ; use appropriate device set match resistance nDPI Good health , except presence asthma , accord medical history physical examination Normal ( i.e . nonclinically significant abnormality ) 12lead electrocardiogram ( ECG ) Negative drug , alcohol , urine cotinine screen ; subject must test negative amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , cotinine ( unless relate nicotinecontaining therapy ) , ethanol , opiate ( unless give prescription medicine ) Nonsmokers exsmokers smoke history le 10 packyears ( e.g . &lt; 20 cigarette per day 10 year 40 cigarette per day 5 year ) stop smoke least one year prior Screening Visit . Smoking permit throughout study Female subject childbearing potential must use medically acceptable form contraception ; approve form contraception abstinence , hormonal ( oral , implant , transdermal , injection , use ≥3 consecutive month start RunIn Period ) , double barrier ( condom spermicide , diaphragm spermicide ) , intrauterine device , vasectomised partner ( ≥6 month since vasectomy ) Regular use ( ≥3 time per week ) topical steroid take treat dermatitis , rhinitis allergic conjunctivitis , within 28 day Screening Visit Subjects upper low respiratory tract infection within 28 day Screening Visit Subjects asthma require admission intensive care unit and/or ventilation within previous 12 month History lung cancer Subjects `` brittle asthma '' , define patient asthma either maintain many month wide variation ( &gt; 40 % ) PEF morning evening measurement despite moderate high dos ICS , prone acute , severe often unpredictable attack asthma may fatal , background apparently good asthma control History current diagnosis human immunodeficiency virus ( HIV ) infection Active chronic hepatitis B C infection . If patient 's screening test positive hepatitis B surface antigen , patient exclude unless investigator , careful review patient 's medical history current laboratory test liver function , exclude possibility recent current infection Persistent arterial hypotension , average systolic blood pressure ( SBP ) read ≤95 mmHg Subjects clinically significant abnormality find examination , test , history may compromise subject safety , specifically history cardiac , renal hepatic impairment Subjects abnormal ECG Persistent elevation blood pressure , average SBP reading ≥160 mmHg average diastolic blood pressure ( DBP ) read ≥100 mmHg Pregnant lactating female Participation another clinical study 28 day prior Screening Visit Current history drug alcohol abuse dependence accord World Health Organization criterion 12 month prior Screening Visit evidence abuse indicate laboratory assay conduct screen evaluation Evidence clinically significant renal , hepatic , cardiac , pulmonary ( apart asthma ) metabolic dysfunction , e.g . diabetes mellitus , thyrotoxicosis , uncorrected hypokalaemia , predisposition low level serum potassium Inability communicate well investigator Evidence clinically significant renal , hepatic , cardiac , pulmonary ( apart asthma ) metabolic dysfunction , e.g . diabetes mellitus , thyrotoxicosis , uncorrected hypokalaemia , predisposition low level serum potassium Donation ≥450 mL blood blood product within previous 12 week prior Screening Visit History allergy , intolerance contraindication corticosteroid , lactose , severe allergy milk proteins Consumption alcohol caffeinecontaining food beverage midnight Screening Visit . The visit reschedule subject excluded History medically diagnose chronic respiratory disease ( asthma ) e.g . chronic obstructive pulmonary disease Subjects previously clinically radiologically diagnosed osteoporosis and/or receive regular treatment ( 1 month duration ) oral parenteral corticosteroid last year prior Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>